Structural Variances Between CJC-1295 and Mod GRF 1-29
Differentiating the two analogues by LC-MS starts with a thorough understanding of their structural differences. Both are synthetic analogues of the naturally occurring GHRH(1-29) sequence. Mod GRF 1-29 contains four specific amino acid substitutions relative to the native sequence: D-Ala2, Gln8, Ala15, and Leu27. These substitutions were introduced to improve structural stability during in vitro handling and to reduce susceptibility to oxidation and rearrangement in aqueous environments. Mod GRF 1-29 carries no further conjugation moiety; it is a C-terminally amidated, tetrasubstituted 29-residue peptide.
CJC-1295 (with DAC) builds upon this framework by adding a lysine residue at position 30. The ε-amine of this specific lysine is acylated with a 3-maleimidopropionyl (MPA) group. The maleimide ring is highly reactive towards free thiols, such as those found on cysteine residues, and forms stable thioether bonds via a Michael addition mechanism. This property is extensively exploited in bioconjugation work to link the peptide to larger carrier proteins in vitro (PMID:15817669). Analytically, the Lys-MPA addition increases the overall molecular weight and adds a hydrophobic, chemically reactive group to the C-terminus. It does not add a basic charge to the molecule, because the lysine ε-amine is covalently capped by the MPA group.
Nomenclature remains a common source of confusion, with Mod GRF 1-29 frequently sold or described under the misleading moniker 'CJC-1295 No DAC'. Relying on labelling without rigorous analytical verification therefore introduces significant risk to the integrity of research protocols. LC-MS remains the most direct and reliable way to confirm whether the Lys-MPA moiety is present or absent in a given sample.
Liquid Chromatography (LC) Retention Time Shifts
The first dimension of analytical differentiation is chromatographic behaviour under reversed-phase high-performance liquid chromatography (RP-HPLC). RP-HPLC separates analytes based on their relative hydrophobicity interactions with a non-polar stationary phase, typically a C8 or C18 column, using a gradient of water (Mobile Phase A) and acetonitrile (Mobile Phase B).
The Lys-MPA addition fundamentally changes the hydrophobic profile of CJC-1295 relative to Mod GRF 1-29. As a result, the two analogues generally show distinctly different retention times under the exact same gradient conditions. The direction and magnitude of the retention time shift depend heavily on the specific column chemistry, gradient steepness, and the chosen mobile phase modifier, so each laboratory must establish its own empirical data with certified reference material rather than assume a universal shift.
Acidic modifiers are standard practice in peptide chromatography. Trifluoroacetic acid (TFA, ~0.1%) acts as an excellent ion-pairing agent and yields exceptionally sharp peptide peaks, but it significantly suppresses the electrospray ionisation signal in the mass spectrometer. Formic acid (~0.1%) is therefore often preferred, or used in combination with very low levels of TFA (e.g., 0.01%), when the column eluent is directed straight into the mass spectrometer. Method development should carefully optimise the gradient slope, column compartment temperature (commonly maintained at 30–40°C to reduce system backpressure), and flow rate to achieve baseline resolution, particularly when assessing mixed samples or investigating potential cross-contamination.
The reactive maleimide group also necessitates extreme care during sample handling and preparation:
- At neutral-to-basic pH levels, and with extended time in aqueous solution, the maleimide ring can hydrolyse to form a maleamic acid derivative (+18 Da). This degradation product typically appears as a separate, closely eluting shifted peak on the chromatogram.
- It can rapidly react with thiol-containing buffer additives such as dithiothreitol (DTT), beta-mercaptoethanol, or free cysteine to form unintended adducts.
To limit both of these analytical artefacts, analysts should exclusively use slightly acidic, strictly thiol-free diluents and analyse the prepared samples promptly. With standardised and validated conditions, laboratories can build highly reproducible retention time reference libraries as a preliminary identity check before proceeding to mass detection (PMID:21204297).
Mass Spectrometry (MS) Intact Mass Analysis
Intact mass analysis provides the most decisive and unambiguous differentiation between the two compounds. Electrospray ionisation (ESI) operated in positive ion mode produces multiply charged peptide ions with minimal in-source fragmentation. For peptides of this specific size and basic residue composition, the dominant charge states observed in the spectrum are typically [M+3H]3+ to [M+6H]6+, depending heavily on the mobile phase pH and the specific instrument tuning parameters. The neutral monoisotopic or average mass is subsequently obtained by mathematical deconvolution algorithms: M = (m/z × z) − (z × 1.00728).
The average molecular weights are approximately 3368 Da for Mod GRF 1-29 and approximately 3647 Da for CJC-1295 (with DAC). This results in a substantial mass shift of roughly 279 Da, corresponding exactly to the added lysine residue plus the maleimidopropionyl group. Exact theoretical monoisotopic values should always be calculated from the confirmed amino acid sequence and known modifications using analytical software, rather than taken from secondary literature sources. For peptides of this mass, the isotopic envelope is broad, and the monoisotopic peak is often not the most abundant isotope, requiring careful spectral interpretation.
A mass difference of 279 Da is unambiguous even on lower-resolution single-quadrupole instruments. However, high-resolution Time-of-Flight (TOF) or Orbitrap mass spectrometry systems add critical mass accuracy, typically measuring within ~5 parts per million (ppm), and easily resolve the complex isotope patterns.
When reviewing the acquired mass spectra, analysts must account for several features that can complicate data interpretation:
- Common metal adducts: sodium (+21.98 Da relative to the protonated species) and potassium (+37.96 Da), which often originate from glassware or solvent impurities.
- TFA adducts, which can form if trifluoroacetic acid is used in the mobile phase without adequate desolvation.
- Maleimide-specific artefacts, including the aforementioned hydrolysis (+18 Da) and unintended thiol adducts.
Accurate intact mass determination remains a fundamental baseline requirement for verifying the exact identity of synthetic GHRH analogues in a research setting (PMID:34665524).
Tandem Mass Spectrometry (MS/MS) Sequence Mapping
While intact mass analysis successfully distinguishes the two analogues at a macro level, tandem mass spectrometry (MS/MS) provides definitive sequence-level confirmation. A specific precursor ion, for example, an abundant 4+ or 5+ charge state, is isolated in the mass spectrometer and subjected to fragmentation by collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD). This energetic process primarily breaks the peptide amide bonds, producing b-ions, which contain the N-terminus of the peptide, and y-ions, which contain the C-terminus.
For Mod GRF 1-29, the observed fragment ions should perfectly match the theoretical b- and y-ion series of the tetrasubstituted 29-residue amidated sequence. Software-assisted spectral matching greatly supports sequence confirmation, although ion coverage may be incomplete in certain internal regions depending on the collision energy applied.
For CJC-1295, the N-terminal b-ions should identically match those of Mod GRF 1-29, as the sequence is identical up to residue 29. The y-ions that contain the C-terminal Lys-MPA, however, are uniformly shifted by the exact mass of the added lysine plus the maleimidopropionyl group. By carefully following this mass shift along the y-ion series, the analyst can definitively localise the structural modification to the C-terminal lysine residue, ruling out modifications elsewhere in the chain.
Furthermore, MS/MS analysis helps detect synthesis-related impurities that intact mass profiling alone might miss, such as:
- Truncated sequences resulting from incomplete coupling during solid-phase peptide synthesis.
- Deletion impurities where a single amino acid was skipped.
- Incorrect amino acid substitutions or isomeric variants.
LC-MS/MS approaches of this highly specific nature are well established and heavily relied upon for the rigorous characterisation of these analogues (PMID:30938069).
Analytical Documentation and COA Verification in Australia
For Australian laboratories, a deep understanding of these analytical methods supports the accurate interpretation of a Certificate of Analysis (COA). A research-grade COA should provide fully traceable, transparent data confirming the exact identity and chromatographic purity of the specific analogue supplied.
Identity should always be checked first in the provided LC-MS data. The COA must clearly state the theoretical mass of the target molecule alongside the experimentally observed mass. For laboratory work that specifically requires CJC-1295 with DAC, the observed mass must reflect the Lys-MPA addition, which is approximately 279 Da above the mass of Mod GRF 1-29. If the observed mass instead matches Mod GRF 1-29, the material is definitively not the DAC analogue, regardless of what the product name on the vial label says.
Chromatographic purity is assessed directly from the HPLC chromatogram and the accompanying peak integration table. Researchers should critically review the main peak area percentage, the integration parameters used by the software, and the retention time against a known reference standard. The most useful and reliable COAs include raw chromatograms, detailed integration tables, and high-resolution mass spectra so that the analytical results can be checked independently, rather than relying on a single summary percentage figure. Pairing this comprehensive documentation with a robust understanding of the structural differences between the analogues helps researchers avoid costly experimental errors arising from ambiguous nomenclature.
Frequently asked questions
What is the primary structural difference between CJC-1295 and Mod GRF 1-29?
CJC-1295 carries a Drug Affinity Complex (DAC). This is an additional C-terminal lysine whose side chain bears a reactive maleimidopropionyl group designed for bioconjugation. Mod GRF 1-29 is the exact same tetrasubstituted 29-residue core sequence without this C-terminal addition.
How does the DAC modification affect the LC-MS intact mass?
The lysine plus maleimidopropionyl addition increases the overall molecular weight by roughly 279 Da (average MW ~3368 Da for Mod GRF 1-29 versus ~3647 Da for CJC-1295). This distinct mass shift is the primary diagnostic metric used to tell the two analogues apart during mass spectrometry.
Why is tandem mass spectrometry (MS/MS) useful for these peptides?
MS/MS fragmentation provides detailed sequence-level information by breaking the peptide into b-ions and y-ions. Shifted y-ions definitively localise the DAC modification to the C-terminal lysine. Fragment analysis also helps detect synthesis errors like truncations, deletions, or incorrect substitutions that intact mass alone may not reveal.
What should Australian researchers look for on a CJC-1295 Certificate of Analysis?
Researchers must check that the observed intact mass matches the theoretical mass of the DAC-modified peptide rather than the unmodified Mod GRF 1-29. Furthermore, look for raw chromatograms, integration tables, and mass spectra that allow for an independent review of both identity and purity.
References
- PMID:15817669 — Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog — Endocrinology — 2005
- PMID:21204297 — Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation — Drug Test Anal — 2010
- PMID:34665524 — Advances in the detection of growth hormone releasing hormone synthetic analogs — Drug Test Anal — 2021
- PMID:30938069 — A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS — Drug Test Anal — 2019
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
